Evidence map›Paper›PMID 41000963›Full record

ArticlebioRxiv : the preprint server for biology2025

Biodistribution-Driven Discovery Identifies a Glycosidase-Cleavable Linker to Reprogram Radiotheranostics.

Woonghee Lee, Sai Reddy Doda, Kwamena E Baidoo, Divya Nambiar, Joon-Yong Chung, Stephen Adler, Elijah Edmondson, Yuki Ueda, Satoshi Omiya, Xiaoyi Li and 12 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Woonghee LeeMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD 20895, USA.ORCID 0000-0003-0279-5268
Sai Reddy DodaChemical Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda, MD 20895, USA.
Kwamena E BaidooMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD 20895, USA.
Divya NambiarMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD 20895, USA.
Joon-Yong ChungMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD 20895, USA.
Stephen AdlerClinical Research Directorate, Frederick National Laboratory for Cancer Research; Frederick, MD 21701, USA.
Elijah EdmondsonMolecular Histopathology Lab, Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research; Frederick, MD 21701, USA.
Yuki UedaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD 20895, USA.
Satoshi OmiyaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD 20895, USA.
Xiaoyi LiChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD 20895, USA.
Hima MakalaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD 20895, USA.
Julia Sheehan-KlenkMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD 20895, USA.
Stanley FaynMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD 20895, USA.ORCID 0000-0003-3313-2934
Orit Jacobson WeissMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD 20895, USA.
Eric LindbergChemical Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda, MD 20895, USA.
Jessica A BeckComparative Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD 20895, USA.
Amy K LeBlancComparative Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD 20895, USA.
Frank I LinMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD 20895, USA.
Peter L ChoykeMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD 20895, USA.
Rolf SwensonChemical Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda, MD 20895, USA.
Martin J SchnermannChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD 20895, USA.ORCID 0000-0002-0503-0116
Freddy E EscorciaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD 20895, USA.ORCID 0000-0002-0727-3242

Funding

Development of new antibody-based cancer therapiesZIABC010891 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HO, MITCHELL · 2009 to 2025
$21.4M
Synthesis and evaluation of small-molecule imaging agentsZIABC011506 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SCHNERMANN, MARTIN · 2013 to 2025
$12.1M
Engineering HCC-selective PET agentZIABC011800 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ESCORCIA, FREDDY · 2018 to 2025
$10.6M
Near-IR Photorelease Chemistry: Discovery and ApplicationsZIABC011564 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SCHNERMANN, MARTIN · 2014 to 2025
$9.5M
Intramural NIH HHS ZIA BC010891Intramural NIH HHS ZIA BC011506Intramural NIH HHS ZIA BC011564Intramural NIH HHS ZIA BC011800
6 · The paper itself

Abstract

While radiopharmaceutical therapy (RPT) has become part of the standard-of-care for patients with advanced prostate cancers and neuroendocrine tumors (NETs), cures are elusive and normal tissue toxicity remain a challenge. Chemical groups susceptible to cleavage by enzymes present in tumors, tumor microenvironment or in normal tissues, have the potential to improve the therapeutic index for RPT. Using DOTA-TATE as an example and drawing from strategies used to develop antibody-drug conjugates, we designed, and synthesized, a chemically diverse series of linkers between the chelator (DOTA) and the targeting vector (TATE). Of the 10 agents we tested, two with cleavable linker domains reduced kidney retention compared to DOTA-TATE: the previously reported DOTA-MVK(ε)-TATE, and a novel agent bearing cleavable beta-galactose (β-Gal) unit, DOTA-β-Gal-TATE. In murine models of NETs, positron emission tomography (PET) was used to image yttrium-86 (

Identifiers

PMID41000963
PMCPMC12458472

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.